The new england journal of medicine publishes data from phase 2b trial of oral orexin receptor 2 agonist oveporexton (tak-861) in people with narcolepsy type 1

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse: 4502/nyse:tak) today announced that the new england journal of medicine published data from the phase 2b trial of oveporexton (tak-861) in people with narcolepsy type 1 (nt1). oveporexton is an investigational oral orexin receptor 2 (ox2r)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes nt1. results demonstrated significant improvement in objective and subjective measure.
TAK Ratings Summary
TAK Quant Ranking